A new biomarker, which is under investigation at Johns Hopkins, shows great potential to address both of these controversial issues.
Early research indicates that a serum assay based on this marker, known as Early Prostate Cancer Antigen-2 (EPCA-2), is both highly sensitive and specific (see, "New marker may be more specific for prostate Ca"). PSA's sensitivity for prostate cancer is in the range of 70%, and its specificity is approximately 64%. By comparison, the figures for EPCA-2 are 94% and 97%, respectively, according to the Hopkins research, led by Robert H. Getzenberg, PhD. While other markers for prostate cancer have been studied, none has demonstrated such high sensitivity and specificity.
The current data on EPCA-2, which need to be validated in larger numbers of patients and at multiple institutions, suggest its potential role in a number of important clinical applications.
Second, a serum assay for EPCA-2 could potentially help urologists determine tumor stage and an appropriate choice of treatment, since the initial research has shown that patients with localized disease do, in fact, have lower levels of EPCA-2 than do patients with either locally advanced or metastatic disease.
Third, if elevated levels of EPCA-2 in the serum are confined to prostate cancer patients and are higher in those with advanced disease, then this new marker may also be able to separate patients who have indolent disease from those with progressive disease.
Fourth, if the gene sequence that codes for EPCA-2 is determined, the potential would exist for identifying patients at risk for the disease-and possibly developing a prevention strategy to use before it actually occurs.
While these applications hold great promise, much more research is needed before they become reality.
Richard D.Williams, MD
Dr. Williams, a Urology Times editorial consultant, is professor and chair, department of urology, University of Iowa, Iowa City.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.